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The review by O’Malley et al.1 adds to the evidence that smoking is an important effect modifier to consider in cancer treatment. Presented is a concise review of the known 
effects of cigarette smoke on phase I/II metabolizing enzymes, pharmacokinetics/phar-
macodymamics, and the metabolism and effectiveness of several systemic lung cancer 
agents. This timely work coincides with new evidence synthesis from the 2014 Surgeon 
General’s Report (SGR) “The Health Consequences of Smoking–50 Years of Progress” 
(US Department of Health and Human Services).2 Updated SGRs over the past 50 years 
have increasingly confirmed that smoking is a risk factor for multiple cancers and for the 
development of several other non-cancer-related health conditions. What is particularly 
noteworthy for oncologists in the 2014 SGR are the following conclusions:
 1.  In patients with cancer and survivors, the evidence is sufficient to conclude a 
causal relationship between cigarette smoking and adverse health outcomes. 
Quitting smoking improves the prognosis of patients with cancer.
 2.  In patients with cancer and survivors, the evidence is sufficient to conclude a 
causal relationship between cigarette smoking and increased all-cause mortality 
and cancer-specific mortality.
 3.  In patients with cancer and survivors, the evidence is sufficient to conclude a 
causal relationship between cigarette smoking and an increased risk of second 
primary cancers known to be caused by cigarette smoking, such as lung cancer.
 4.  In patients with cancer and survivors, the evidence is suggestive but not sufficient 
to conclude a causal relationship between cigarette smoking and the risk of disease 
recurrence, poorer response to treatment, and increased treatment-related toxicity.
These conclusions are the first large evidence assessment that causally associates 
tobacco smoking with adverse health outcomes in patients with cancer. The review pro-
vided by O’Malley et al.1 is a noteworthy contribution, highlighting an important facet of 
a complex question in cancer care: what are the true adverse effects of smoking on cancer 
treatment and what can be done to deal with these adverse effects?
To begin to understand the depth of this question, we must first recognize the ever 
increasing complexity of modern cancer care. Oncologists are tasked with coordinating 
multiple facets of patient care centered around diagnosis and workup, treatment, assessing 
response, managing toxicity, and arranging follow-up. Each step requires assessment of a 
patient’s comorbid condition and an understanding of each patient’s behavioral, social, and 
financial environment. Oncologists have access to a broad variety of up-to-date resources, 
often delivered by daily emails, that highlight advances in cancer research and clinical care 
that often emphasize the potential utility of new biological agents, potentially new genomic 
prognosticators, and industry sponsored communication that advocate for the use of new 
agents in cancer care. Many of these new potential advances are untested in large trials and 
may not accurately reflect clinical effect or impact, but may still garner the attention of 
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/14/0907-0914
Cigarette Smoking and Systemic Therapy for Lung Cancer
Considering the Evidence to Improve Cancer Care
Graham W. Warren, MD, PhD*†
*Department of Radiation Oncology; and †Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC.
Disclosure: Dr. Warren is supported in part through funding by the American Cancer Society (MRSG-11-031-01-CCE). The author declares no conflict of interest.
Address for correspondence: Graham W. Warren, MD, PhD, Department of Radiation Oncology, Medical University of South Carolina, 169 Ashley Ave. MSC 
318. Charleston, SC 29425. E-mail: warrengw@musc.edu
XXX
Editorial
915Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 7, July 2014 Systemic Therapy for Lung Cancer
widespread media coverage.3 The complexity of tumor biol-
ogy coupled with increasingly complex cancer care requires 
careful consideration of how to integrate this widespread 
knowledge base into functional clinical practice.4 Importantly, 
this complexity and the stress associated with cancer care can 
result in high rates of burnout for oncologists.5 As a result, 
clinicians and researchers should carefully frame advances in 
cancer research or clinical cancer care in a light that is easily 
understood and implemented into standard clinical practice.
Addressing tobacco use by cancer patients may seem 
relatively easy to implement, but there has been proportion-
ately little work on this topic. The 2014 SGR certainly pro-
vides the necessary justification to address smoking by cancer 
patients.2 Taken as a whole for cancer patients, current smok-
ing increases the risk of overall mortality by a median of 
approximately 50% and increases the risk for cancer-related 
mortality by approximately 60%.2 In contrast, former smoking 
increases the risk of overall mortality by approximately 20% 
with no appreciable overall effect on cancer-related mortality. 
These data suggest that the effects of smoking are reversible. 
However, data are lacking on the magnitude of clinical ben-
efit achieved with smoking cessation after a cancer diagnosis. 
There are no good data that clarify whether complete absti-
nence is required to improve cancer treatment outcomes or 
what amount of time of “complete abstinence” is required to 
prevent the adverse effects of current smoking. A very practi-
cal clinical question pertains to whether a “harm reduction” 
strategy, broadly defined as a significant reduction in daily 
cigarette smoking or switching to alternative tobacco prod-
ucts,6 is useful to decrease or eliminate the harmful effects of 
smoking. On a more fundamental level, a variety of defini-
tions for tobacco use limit discrete analyses and interpretation 
of clinical cancer treatment outcomes as related to tobacco 
use.7 There are currently no standardized questions to assess 
smoking by cancer patients advocated by any national or inter-
national organization. A recent survey of active cooperative 
group clinical trials demonstrates that over 70% do not assess 
any form of tobacco use whatsoever and 95% do not assess 
tobacco use in follow-up assessments.8 As a result, we are 
unlikely to glean well structured evidence or guidance from 
current clinical research activities. We are further unlikely to 
understand the metabolic or pharmacokinetics/pharmacody-
mamics effects of current smoking discussed by O’Malley et 
al.1 on investigational agents or if the effects of smoking are 
reversible within the timeframe of cancer treatment.
O’Malley et al.1 touch on a brief discussion of the effects 
of smoking on cancer biology. Whereas thousands of studies 
confirm the carcinogenic effects of smoking as related to the 
risks of developing cancer,2 there have been very few studies 
on the effects of smoking in cancer cells. However, O’Malley 
et al.1 reference metabolic changes in tyrosine kinase inhibi-
tors leading to differences in therapeutic response, but others 
have also shown that oxidative stress from cigarette smoke can 
result in epidermal growth factor receptor autophosphoryla-
tion and subsequent activation of the Ras/Raf/MEK/ERK and 
PI3K/Akt pathways leading to epidermal growth factor recep-
tor-tyrosine kinase inhibitors resistance.9,10 The authors also 
highlight reviews of the tumor promoting activities of nicotine 
and the nicotinic acetylcholine receptor, but these data are 
based upon preclinical systems using cell cultures and animal 
models.11 There are no studies of the clinical effects of nico-
tine or nicotinic agonists in cancer patients. Understanding 
the effects of smoking and tobacco-related products on cancer 
biology and therapeutic response in cancer patients is largely 
unexplored. However, as noted in Table 1 by O’Malley et al.,1 
the decrease in neutropenia associated with current smoking 
could very well be attributed to changes in drug metabolism 
or, in part, because of decreases in chemotherapy-induced 
apoptosis from exposure to chemicals in cigarette smoke.11 
Notably, both the American Association for Cancer Research 
and American Society for Clinical Oncology have published 
recent updates advocating for tobacco cessation in clinical 
practice and research for cancer patients.12,13 Both American 
Association for Cancer Research and American Society for 
Clinical Oncology advocate for the use of nicotine replace-
ment therapy as an evidence based pharmacotherapy for 
tobacco cessation support. Until evidence clearly defines a 
harmful role for nicotine in cancer care, clinicians should not 
be reticent to use nicotine-based agents if they can be useful to 
promote smoking cessation in cancer patients.
In their conclusions, O’Malley et al.1 discuss potential 
improvements in clinical response relating to alterations in the 
dose of systemic agents. Many paradigms in cancer care are 
based upon the predilection that increasing dose will increase 
response. Certainly, as noted by the authors, “…a dose-
response effect of lung cancer specific systemic therapies in 
smokers” has yet to be determined. Previously, the authors note 
that “…the most crucial intervention is smoking cessation.” 
The question remains whether more efficacious improvements 
in cancer care can be generated through a change in systemic 
cancer agent dose versus potential changes in cancer response 
and changes in non-cancer–related comorbidity associated 
with smoking cessation. In reality, some combination of the 
two will likely yield the optimal outcome. However, there are 
no clinical trials that have considered systemic agent dose 
modification in combination with structured tobacco cessa-
tion support to improve cancer treatment outcomes.
Prior arguments have been made that the effects of smok-
ing by cancer patients may be as significant at the therapeutic 
gains of new chemotherapeutic agents.14 The evidence necessary 
to develop treatment strategies for cancer patients who smoke at 
diagnosis does not yet exist. The authors conclude, “…clinical 
trials should take this factor into consideration and potentially 
use it as an independent predictive variable when designing stud-
ies of personalized medicine that includes smoking status.” This 
is undoubtedly true, but clinicians and researchers should fur-
ther consider that the effects of smoking are widespread across 
cancer disease sites and treatments, associated with a more 
aggressive tumor biology and phenotype, associated with poorer 
compliance to cancer treatment, can lead to changes in drug 
metabolism, may affect cancer treatment outcomes through non-
cancer–`related clinical comorbidities, and may be reversible 
with effective smoking cessation strategies.2,15 The metabolic 
changes associated with smoking in the noteworthy contribution 
by O’Malley et al.1 are very likely the tip of the iceberg sub-
merged in the waters of advances in cancer care.
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